Floatz logo

Iparomlimab

Neoadjuvant Immunotherapy

Tianjin Medical University Cancer Institute and HospitalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Neoadjuvant Immunotherapy cohort.

Asset / SponsorPhaseRating
Tisleizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Catequentinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
FALLYPRIDE
Shanghai Pulmonary Hospital, Shanghai, China
D
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Shanghai Pulmonary Hospital, Shanghai, China
D

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
ES-SCLCDormant
BB
Indicative ·
70 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →